RxDoctor Payments Data

Rachelle Dambman

Adult Health · Newark, DENPI 1124626064

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 29.4% of the total. Reporting peaked in 2024 at $923 and has fallen 91.5% since, to $78 in 2025.

$1,901in general payments, 2019–2025

Across 97 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$560
  • Gilead$330
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$248
  • Ardelyx, Inc.$113
  • Johnson & Johnson$107
  • Shield Therapeutics Inc$104
  • plus $440 from 13 others

What the payments were for

  • Food & beverage$1,901100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,901 in reported general payments places this provider in the 80th percentile of 65 adult health providers in Delaware.

See all adult health providers in Delaware

Medicare billing

Part B allowed, 2024
$9,477
Medicare patients
96
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin25$79,907
RezdiffraResmetirom17$66,405
CreonLipase/Protease/Amylase21$51,129
LinzessLinaclotide46$37,728
MovantikNaloxegol Oxalate11$4,452
Omeprazole129$2,063
Cholestyramine LightCholestyramine17$1,534
Lubiprostone16$1,532
Pantoprazole Sodium83$1,014
Budesonide EcBudesonide13$897
Famotidine61$808
Lactulose18$584
Spironolactone18$367
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl24$345
Sulfasalazine DrSulfasalazine12$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$560$88,85767 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$248$79,90725 claims
Madrigal PharmaceuticalsRezdiffra$17$66,40517 claims
Redhill Biopharma Inc.Movantik$32$4,45211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 65 adult health providers in Delaware.

Other adult health in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →